In-Office Procedures · Treatment
OptiLight by Lumenis: Intense Pulsed Light for Dry Eye
The first and only IPL device FDA-cleared for the management of dry eye disease due to MGD. Backed by more than 50 peer-reviewed clinical studies. Included in TFOS DEWS III.
Key points
- Manufacturer direct through Lumenis.
- The first and only IPL device FDA-cleared for dry eye due to MGD.
- Light pulses target periocular inflammation and abnormal vessels.
- Commonly delivered as a short series, often paired with gland expression.
How it works
OptiLight delivers precise, filtered broad-spectrum light pulses (500 to 600 nm) to the periocular skin below and around the eyes. The mechanism is multi-factorial:
- Abnormal vessel ablation, targets telangiectatic vessels around the eyelid margin that serve as routes for inflammatory mediator influx into the meibomian glands
- Inflammatory mediator reduction, IPL reduces local concentrations of IL-6, IL-1, and MMP-9 in periocular tissue
- Thermal meibomian gland effect, light absorbed by periocular structures generates heat that softens meibomian gland secretions
- Demodex reduction, IPL has demonstrated antimicrobial effects against Demodex mites on the lid margin
OptiLight is typically delivered as a series of four treatments spaced 2 to 4 weeks apart, followed by meibomian gland expression during or after each session. Maintenance treatments are recommended every 6 to 12 months.
FDA clearance
OptiLight received FDA clearance in April 2021 for the management of dry eye disease due to meibomian gland dysfunction, the first and only IPL device cleared for this indication in the United States. This clearance required Lumenis to submit rigorous safety and efficacy data from prospective clinical trials.
Clinical evidence
- Toyos et al. (2022, PLOS ONE), Landmark randomized controlled trial: IPL + meibomian gland expression compared with gland expression alone. 56% of IPL-treated eyes exceeded 3-second TBUT improvement compared with 26% in the control group (p<0.001). PLOS ONE
- Yin et al. (2018, Current Eye Research), IPL improved both the structure and function of meibomian glands, with statistically significant increases in meibum secretion quality and gland morphology scores. PubMed
- Liu et al. (2017, American Journal of Ophthalmology), IPL reduces inflammatory markers (MMP-9, IL-6) in the tear film associated with chronic dry eye, with sustained reduction at 3-month follow-up. PubMed
- Castro et al. (2023, Cureus), Comparative study of three light-based devices for MGD. Lumenis M22 (OptiLight platform) demonstrated superior improvement in meibomian gland secretory index, first NIBUT, and fluorescein TBUT compared to E>Eye (IRPL) device. Cureus
- 80 to 90% patient improvement, Across multiple clinical trials, 80 to 90% of patients completing a full OptiLight treatment series report significant improvement in dry eye symptoms. Clinical summary, The Last Optical
- TFOS DEWS III Management Report (2025), IPL supported as an effective, safe approach for moderate-to-advanced MGD with growing clinical trial evidence demonstrating reduction in symptoms and signs of DED, improved optical quality, and reduced tear supplementation dependence. American Journal of Ophthalmology
Combination therapy
OptiLight is most effective when followed immediately by meibomian gland expression. Many practices sequence OptiLight with BlephEx lid debridement (before) and either LipiFlow, TearCare, or iLux2 expression (after) as part of a comprehensive MGD treatment day.
Manufacturer
Lumenis, OptiLight product page
Sources are linked inline above. Device descriptions reference FDA clearance status, published peer-reviewed studies, and manufacturer data. Clinical outcomes are not a guarantee of individual results. Review full prescribing information, the IFU, and FDA clearance documentation for each device before use.
